Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors
These results indicate that maintenance therapy using anlotinib combined with sintilimab could be a safe and effective treatment option for advanced pediatric tumors.
Authors
- Ruijuan He
- Rui Zhao (ORCID: https://orcid.org/0000-0002-6602-6583)
- Liang Chang (ORCID: https://orcid.org/0000-0001-7220-0544)
- Xudong Wei (ORCID: https://orcid.org/0000-0002-3325-0837)
- Chengyi Zhang (ORCID: https://orcid.org/0000-0002-9190-2282)
Institutions
- City of Hope (US)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-10
- DOI
- https://doi.org/10.3389/fonc.2025.1518987
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China